Leadership Team
Dr. Nancy Stagliano, Chief Executive Officer
Nancy Stagliano, Ph.D. joined iPierian as Chief Executive Officer in September 2011 with an accomplished career as a biotech leader spanning all aspects of the industry, from discovery research and strategy to global medical affairs and corporate communications. Prior to joining iPierian, Dr. Stagliano was CEO of CytomX Therapeutics, a company where she was co-founder and a lead inventor on the patents for CytomX’s Probody platform. In earlier roles with CytomX, she served as the COO of CytomX LLC, which launched CytomX Therapeutics as well as Cynvenio Biosystems. Before moving to California, Nancy joined the Cambridge, Massachusetts, biotechnology industry in the late 1990s, where she had an eight-year tenure at Millennium Pharmaceuticals and consulted to several local startups. Dr. Stagliano received her BS in Electrical Engineering and her MS in Biomedical Engineering, both from Drexel University in Philadelphia. She obtained her PhD in Neuroscience from the University of Miami, followed by three years as an independently-funded research fellow at the Massachusetts General Hospital and Harvard Medical School, where she studied mechanisms of brain injury after stroke.
Dr. Pamela B. Conley, Ph.D., Vice President of Research
Pamela Conley, Ph.D., joined iPierian as Vice President of Research in April 2012. Prior to joining iPierian, Dr. Conley was Vice President of Research Biology at Portola Pharmaceuticals where she was involved in the successful identification and clinical progression of both small molecule and biologic therapeutics in the areas of thrombosis, coagulation and inflammation. Prior to joining Portola in 2003, Dr. Conley was a Director in Biology at Millennium, responsible for the basic research and drug discovery efforts for the P2Y12 program, as well as identification of novel platelet targets through expression profiling studies. Dr. Conley joined COR Therapeutics in 1991, where she initiated the program to identify novel inhibitors of platelet ADP receptors. Dr. Conley’s group was responsible for cloning and identification of the P2Y12 receptor, published in Nature in 2001. She is the author of over 50 scientific publications and reviews, as well as an inventor on multiple patents. Dr. Conley received her B.A. degree in Biochemistry from the University of Texas at Austin, and her Ph.D. in Biochemistry from the University of California, Berkeley. Afterwards, she worked as a postdoctoral fellow studying gene expression and mammalian transcription factors at Stanford University and the Howard Hughes Medical Institute, Stanford Medical School.
Dr. Adam Rosenthal, Senior Director of Strategic and Corporate Development
Adam Rosenthal, Ph.D., has served as iPierian’s Senior Director of Strategic and Corporate Development since August 2010, working across Finance, Business Development, R&D, and Operations. Prior to joining iPierian, Dr. Rosenthal was a Project Leader at the Boston Consulting Group, working with Fortune 500 pharmaceutical companies in the areas of R&D, operations, and corporate strategy. Prior to joining BCG, he worked at MIT’s Technology Licensing Office, commercializing MIT technology through startup formation and collaborations with industry. Dr. Rosenthal received his Ph.D. in Biomedical Engineering from Harvard and MIT, studying stem cells using lab-on-a-chip technology. He was the recipient of several graduate fellowships, including the National Science Foundation and MIT Presidential fellowships. Dr. Rosenthal holds a Master of Engineering degree from MIT in Electrical Engineering & Computer Science, and dual B.S. degrees from MIT in Electrical Engineering and Brain and Cognitive Science.
Dr. Irene Griswold-Prenner, Senior Director of Cell Biology
Irene Griswold-Prenner, Ph.D., is Senior Director of Cell Biology and has been at iPierian since October 2009. She has over 13 years of experience in the biotech industry. Previously she was Senior Scientist at Elan Pharmaceuticals focusing on target identification, validation, and drug discovery efforts in Alzheimer’s disease, Parkinson’s disease, and Multiple Sclerosis. To date, she has contributed to target and drug discovery efforts in neurodegenerative disease, cancer, and vision. These efforts have resulted in several peer-reviewed publications and patents. Dr. Griswold-Prenner obtained a bachelor’s degree in Molecular, Cellular, and Developmental Biology at the University of Colorado and a Ph.D. in Pharmacology and Cellular Physiology at the University of Chicago studying EGF receptor and MAP kinase signaling pathways. Her postdoctoral research was conducted at UCSF identifying TGF-beta receptor signaling pathways leading to anti-proliferative effects and regulation of extracellular matrix protein production.
Dr. Graham Parry, Director of Translational Research
Graham Parry, Ph.D., is Director of Translational Research and joined iPierian in March 2012. He has over 10 years of experience in drug discovery and pre-clinical development in the biotech industry. Previously, he was Director of Biology at Attenuon LLC, where he was involved in the development of two drugs that entered Phase II clinical trials and where he discovered an antibody targeting the urokinase receptor (uPAR) with robust anti-tumor activity. More recently Dr. Parry has worked with San Diego based Motility Inc. and directed the preclinical development of a novel biotherapeutic with applications in oncology and ophthalmology. Dr. Parry has published 45 original articles in refereed journals, several book chapters and reviews, and is co-inventor on 6 pending or issued patents. Dr. Parry obtained a bachelor’s degree in Applied Biology at Brunel University and a Ph.D. in Biochemistry from the University of London. His postdoctoral research was conducted at The Scripps Research Institute and focused on the regulation of endothelial cell gene expression, coagulation and fibrinolysis.